{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T12:13:50Z","timestamp":1789647230600,"version":"4.0.0"},"reference-count":116,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T00:00:00Z","timestamp":1750032000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Interdisciplinary Research Centre (IZKF) and Deutsche Forschungsgemeinschaft","award":["493624047"],"award-info":[{"award-number":["493624047"]}]},{"DOI":"10.13039\/501100009379","name":"Interdisziplin\u00e4res Zentrum f\u00fcr Klinische Forschung, Universit\u00e4tsklinikum W\u00fcrzburg","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009379","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003042","name":"Else Kroner-Fresenius Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.ymgme.2025.109176","type":"journal-article","created":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T11:40:37Z","timestamp":1750074037000},"page":"109176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Antioxidant therapy in inborn metabolic diseases"],"prefix":"10.1016","volume":"145","author":[{"given":"Felix","family":"Heimes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea-Sophie","family":"Berendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana","family":"Hannibal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2025.109176_bb0005","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s10545-015-9893-x","article-title":"Quo vadis: the re-definition of \u201cinborn metabolic diseases\u201d","volume":"38","author":"Morava","year":"2015","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2025.109176_bb0010","doi-asserted-by":"crossref","DOI":"10.7189\/jogh.08.021102","article-title":"Global birth prevalence and mortality from inborn errors of metabolism: a systematic analysis of the evidence","volume":"8","author":"Waters","year":"2018","journal-title":"J. Glob. Health"},{"key":"10.1016\/j.ymgme.2025.109176_bb0015","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/jimd.12086","article-title":"Proposal for a simplified classification of IMD based on a pathophysiological approach: a practical guide for clinicians","volume":"42","author":"Saudubray","year":"2019","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2025.109176_bb0020","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/jimd.12348","article-title":"ICIMD advisory group, an international classification of inherited metabolic disorders (ICIMD)","volume":"44","author":"Ferreira","year":"2021","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2025.109176_bb0025","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1002\/anie.198610581","article-title":"Biochemistry of oxidative stress","volume":"25","author":"Sies","year":"1986","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.ymgme.2025.109176_bb0030","series-title":"Developments in Cardiovascular Medicine","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4615-4649-8_1","article-title":"What is oxidative stress?","author":"Sies","year":"2000"},{"key":"10.1016\/j.ymgme.2025.109176_bb0035","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1023\/A:1015634032042","article-title":"Oxidative stress in inborn errors of metabolism: lessons from glutathione deficiency","volume":"25","author":"Ristoff","year":"2002","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2025.109176_bb0040","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ymgme.2009.06.007","article-title":"Profiling of oxidative stress in patients with inborn errors of metabolism","volume":"98","author":"Mc Guire","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109176_bb0045","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cophys.2019.04.024","article-title":"Redox signaling in inherited diseases of metabolism","volume":"9","author":"Jacobsen","year":"2019","journal-title":"Curr. Opin. Physio."},{"key":"10.1016\/j.ymgme.2025.109176_bb0050","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s10545-012-9545-3","article-title":"Functional characterization of novel genotypes and cellular oxidative stress studies in propionic acidemia","volume":"36","author":"Gallego-Villar","year":"2013","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2025.109176_bb0055","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1093\/hmg\/ddy403","article-title":"Mitochondrial energetics is impaired in very long-chain acyl-CoA dehydrogenase deficiency and can be rescued by treatment with mitochondria-targeted electron scavengers","volume":"28","author":"Seminotti","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymgme.2025.109176_bb0060","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1146\/annurev.nu.16.070196.000341","article-title":"Antioxidants in human health and disease","volume":"16","author":"Halliwell","year":"1996","journal-title":"Annu. Rev. Nutr."},{"key":"10.1016\/j.ymgme.2025.109176_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114606","article-title":"Cellular red-ox system in health and disease: the latest update","volume":"162","author":"Jena","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ymgme.2025.109176_bb0070","doi-asserted-by":"crossref","first-page":"228","DOI":"10.4161\/oxim.3.4.12858","article-title":"Exogenous antioxidants--Double-edged swords in cellular redox state: Health beneficial effects at physiologic doses versus deleterious effects at high doses","volume":"3","author":"Bouayed","year":"2010","journal-title":"Oxidative Med. Cell. Longev."},{"key":"10.1016\/j.ymgme.2025.109176_bb0075","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41580-023-00645-4","article-title":"Understanding mechanisms of antioxidant action in health and disease","volume":"25","author":"Halliwell","year":"2023","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ymgme.2025.109176_bb0080","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1749-6632.1987.tb23761.x","article-title":"Interaction of ascorbate and alpha-tocopherol","volume":"498","author":"Niki","year":"1987","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"Suppl","key":"10.1016\/j.ymgme.2025.109176_bb0085","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.mito.2007.02.006","article-title":"The antioxidant role of coenzyme Q","volume":"7","author":"Bentinger","year":"2007","journal-title":"Mitochondrion"},{"key":"10.1016\/j.ymgme.2025.109176_bb0090","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.biocel.2014.01.020","article-title":"Coenzyme Q10 as a therapy for mitochondrial disease","volume":"49","author":"Hargreaves","year":"2014","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.ymgme.2025.109176_bb0095","article-title":"Patients with Gaucher disease display systemic oxidative stress dependent on therapy status","volume":"25","author":"Kartha","year":"2020","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2025.109176_bb0100","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0022-3476(67)80019-2","article-title":"Oral administration of n-acetyl cysteine in the prophylaxis of \u201cmeconium ileus equivalent\u201d","volume":"71","author":"Lillibridge","year":"1967","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2025.109176_bb0105","author":"World Health Organization (WHO)"},{"key":"10.1016\/j.ymgme.2025.109176_bb0110","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/BF01061422","article-title":"Pharmacokinetics and bioavailability of reduced and oxidized N-acetylcysteine","volume":"34","author":"Olsson","year":"1988","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ymgme.2025.109176_bb0115","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/BF00606662","article-title":"Pharmacokinetics of N-acetylcysteine in man","volume":"31","author":"Borgstr\u00f6m","year":"1986","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ymgme.2025.109176_bb0120","first-page":"382","article-title":"Pharmacokinetics and bioavailability of oral acetylcysteine in healthy volunteers","volume":"39","author":"De Caro","year":"1989","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.ymgme.2025.109176_bb0125","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1046\/j.1365-2362.2000.00736.x","article-title":"N-acetylcysteine replenishes glutathione in HIV infection: GSH replenishment in HIV-infection","volume":"30","author":"De Rosa","year":"2000","journal-title":"Eur. J. Clin. Investig."},{"key":"10.1016\/j.ymgme.2025.109176_bb0130","doi-asserted-by":"crossref","first-page":"762","DOI":"10.2146\/ajhp060425","article-title":"Stability of acetylcysteine solution repackaged in oral syringes and associated cost savings","volume":"64","author":"Kiser","year":"2007","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.ymgme.2025.109176_bb0135","doi-asserted-by":"crossref","first-page":"344","DOI":"10.4212\/cjhp.v74i4.3082","article-title":"Stability of N-acetylcysteine 60 mg\/mL in extemporaneously compounded injectable solutions","volume":"74","author":"Friciu","year":"2021","journal-title":"Can. J. Hosp. Pharm."},{"key":"10.1016\/j.ymgme.2025.109176_bb0140","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.annemergmed.2004.05.014","article-title":"Status epilepticus after a massive intravenous N-acetylcysteine overdose leading to intracranial hypertension and death","volume":"44","author":"Bailey","year":"2004","journal-title":"Ann. Emerg. Med."},{"key":"10.1016\/j.ymgme.2025.109176_bb0145","doi-asserted-by":"crossref","first-page":"755","DOI":"10.3109\/15563650.2011.609821","article-title":"Hemolysis and hemolytic uremic syndrome following five-fold N-acetylcysteine overdose","volume":"49","author":"Mullins","year":"2011","journal-title":"Clin. Toxicol. (Phila.)"},{"key":"10.1016\/j.ymgme.2025.109176_bb0150","first-page":"3143","article-title":"Glutathione synthesis","volume":"2013","author":"Lu","year":"1830","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymgme.2025.109176_bb0155","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.coph.2007.04.005","article-title":"N-Acetylcysteine--a safe antidote for cysteine\/glutathione deficiency","volume":"7","author":"Atkuri","year":"2007","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.ymgme.2025.109176_bb0160","doi-asserted-by":"crossref","first-page":"9949453","DOI":"10.1155\/2021\/9949453","article-title":"N-acetylcysteine: a review of clinical usefulness (an old drug with new tricks)","volume":"2021","author":"Schwalfenberg","year":"2021","journal-title":"J. Nutr. Metab."},{"key":"10.1016\/j.ymgme.2025.109176_bb0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10715762.2018.1468564","article-title":"N-acetylcysteine as an antioxidant and disulphide breaking agent: the reasons why","volume":"52","author":"Aldini","year":"2018","journal-title":"Free Radic. Res."},{"key":"10.1016\/j.ymgme.2025.109176_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107916","article-title":"The mechanism of action of N-acetylcysteine (NAC): the emerging role of H2S and sulfane sulfur species","volume":"228","author":"Pedre","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ymgme.2025.109176_bb0175","doi-asserted-by":"crossref","first-page":"17205","DOI":"10.1016\/S0021-9258(19)77815-6","article-title":"Glutathione metabolism and its selective modification","volume":"263","author":"Meister","year":"1988","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2025.109176_bb0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mam.2008.08.006","article-title":"Glutathione: overview of its protective roles, measurement, and biosynthesis","volume":"30","author":"Forman","year":"2009","journal-title":"Mol. Asp. Med."},{"key":"10.1016\/j.ymgme.2025.109176_bb0185","first-page":"4117","article-title":"The chemistry and biological activities of N-acetylcysteine","volume":"2013","author":"Samuni","year":"1830","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymgme.2025.109176_bb0190","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s13311-015-0404-4","article-title":"Neuronal glutathione content and antioxidant capacity can be normalized in situ by N-acetyl cysteine concentrations attained in human cerebrospinal fluid","volume":"13","author":"Reyes","year":"2016","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.ymgme.2025.109176_bb0195","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0140-6736(13)62062-0","article-title":"Reduction of adverse effects from intravenous acetylcysteine treatment for paracetamol poisoning: a randomised controlled trial","volume":"383","author":"Bateman","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ymgme.2025.109176_bb0200","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.braindev.2020.10.003","article-title":"Valine-restricted diet for patients with ECHS1 deficiency: divergent clinical outcomes in two Japanese siblings","volume":"43","author":"Sato-Shirai","year":"2021","journal-title":"Brain and Development"},{"key":"10.1016\/j.ymgme.2025.109176_bb0205","article-title":"L-cysteine supplementation prevents liver transplantation in a patient with TRMU deficiency","volume":"19","author":"Soler-Alfonso","year":"2019","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2025.109176_bb0210","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/sj.bmt.1705571","article-title":"N-acetyl-L-cysteine improves outcome of advanced cerebral adrenoleukodystrophy","volume":"39","author":"Tolar","year":"2007","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.ymgme.2025.109176_bb0215","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s13311-019-00735-2","article-title":"Biomarker identification, safety, and efficacy of high-dose antioxidants for adrenomyeloneuropathy: a phase II pilot study","volume":"16","author":"Casasnovas","year":"2019","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.ymgme.2025.109176_bb0220","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S1474-4422(14)70142-5","article-title":"Oral cysteamine bitartrate and N-acetylcysteine for patients with infantile neuronal ceroid lipofuscinosis: a pilot study","volume":"13","author":"Levin","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymgme.2025.109176_bb0225","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/WNF.0b013e31829ae713","article-title":"N-acetylcysteine boosts brain and blood glutathione in Gaucher and Parkinson diseases","volume":"36","author":"Holmay","year":"2013","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.ymgme.2025.109176_bb0230","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1080\/10715760600617843","article-title":"Coenzyme Q10: absorption, tissue uptake, metabolism and pharmacokinetics","volume":"40","author":"Bhagavan","year":"2006","journal-title":"Free Radic. Res."},{"key":"10.1016\/j.ymgme.2025.109176_bb0235","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s10517-008-0270-8","article-title":"Pharmacokinetics of coenzyme q10","volume":"146","author":"Kalenikova","year":"2008","journal-title":"Bull. Exp. Biol. Med."},{"key":"10.1016\/j.ymgme.2025.109176_bb0240","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jff.2008.09.010","article-title":"A randomized, double-blind trial on the bioavailability of two CoQ10 formulations","volume":"1","author":"Evans","year":"2009","journal-title":"J. Funct. Foods"},{"key":"10.1016\/j.ymgme.2025.109176_bb0245","doi-asserted-by":"crossref","first-page":"7174","DOI":"10.1021\/jf5017829","article-title":"Increased bioavailability of ubiquinol compared to that of ubiquinone is due to more efficient micellarization during digestion and greater GSH-dependent uptake and basolateral secretion by Caco-2 cells","volume":"62","author":"Failla","year":"2014","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.ymgme.2025.109176_bb0250","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3390\/antiox10030360","article-title":"Stability of reduced and oxidized coenzyme Q10 in finished products","volume":"10","author":"Temova Raku\u0161a","year":"2021","journal-title":"Antioxidants (Basel)"},{"key":"10.1016\/j.ymgme.2025.109176_bb0255","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.yrtph.2006.05.006","article-title":"Risk assessment for coenzyme Q10 (Ubiquinone)","volume":"45","author":"Hathcock","year":"2006","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.ymgme.2025.109176_bb0260","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1212\/WNL.36.1.45","article-title":"Treatment of Kearns-Sayre syndrome with coenzyme Q10","volume":"36","author":"Ogasahara","year":"1986","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2025.109176_bb0265","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0022-510X(98)00296-2","article-title":"Effect of coenzyme Q10 in patients with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS): evaluation by noninvasive tissue oximetry","volume":"162","author":"Abe","year":"1999","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.ymgme.2025.109176_bb0270","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/mus.21758","article-title":"A randomized trial of coenzyme Q10 in mitochondrial disorders: CoQ10and mitochondrial disease","volume":"42","author":"Glover","year":"2010","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymgme.2025.109176_bb0275","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.mito.2012.09.005","article-title":"Design and implementation of the first randomized controlled trial of coenzyme CoQ\u2081\u2080 in children with primary mitochondrial diseases","volume":"12","author":"Stacpoole","year":"2012","journal-title":"Mitochondrion"},{"key":"10.1016\/j.ymgme.2025.109176_bb0280","author":"de Grauw"},{"key":"10.1016\/j.ymgme.2025.109176_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2020.101812","article-title":"Idebenone: when an antioxidant is not an antioxidant","volume":"38","author":"Gueven","year":"2021","journal-title":"Redox Biol."},{"key":"10.1016\/j.ymgme.2025.109176_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102434","article-title":"Idebenone does not inhibit disability progression in primary progressive MS","volume":"45","author":"Kosa","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.ymgme.2025.109176_bb0295","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jneuroim.2013.07.002","article-title":"The antioxidant idebenone fails to prevent or attenuate chronic experimental autoimmune encephalomyelitis in the mouse","volume":"262","author":"Fiebiger","year":"2013","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.ymgme.2025.109176_bb0300","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1212\/01.WNL.0000096376.03678.C1","article-title":"Idebenone treatment fails to slow cognitive decline in Alzheimer\u2019s disease","volume":"61","author":"Thal","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2025.109176_bb0305","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1021\/tx970136j","article-title":"Antioxidant properties of 2,3-dimethoxy-5-methyl- 6-(10-hydroxydecyl)-1,4-benzoquinone (Idebenone)","volume":"11","author":"Mordente","year":"1998","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.ymgme.2025.109176_bb0310","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0017963","article-title":"NQO1-dependent redox cycling of idebenone: effects on cellular redox potential and energy levels","volume":"6","author":"Haefeli","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2025.109176_bb0315","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0036153","article-title":"Features of idebenone and related short-chain quinones that rescue ATP levels under conditions of impaired mitochondrial complex I","volume":"7","author":"Erb","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2025.109176_bb0320","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00228-008-0596-1","article-title":"Pharmacokinetics and metabolism of idebenone in healthy male subjects","volume":"65","author":"Bodmer","year":"2009","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"Suppl. 1","key":"10.1016\/j.ymgme.2025.109176_bb0325","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00415-009-1006-z","article-title":"Pharmacokinetic properties and metabolism of idebenone","volume":"256","author":"Kutz","year":"2009","journal-title":"J. Neurol."},{"key":"10.1016\/j.ymgme.2025.109176_bb0330","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1001\/archneur.64.6.803","article-title":"Safety, tolerability, and pharmacokinetics of high-dose idebenone in patients with Friedreich ataxia","volume":"64","author":"Di Prospero","year":"2007","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.ymgme.2025.109176_bb0335","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1093\/brain\/awr170","article-title":"A randomized placebo-controlled trial of idebenone in Leber\u2019s hereditary optic neuropathy","volume":"134","author":"Klopstock","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.ymgme.2025.109176_bb0340","doi-asserted-by":"crossref","first-page":"461","DOI":"10.5301\/ejo.5000055","article-title":"Meta-analysis of the prevalence of Leber hereditary optic neuropathy mtDNA mutations in Europe","volume":"22","author":"Mascialino","year":"2012","journal-title":"Eur. J. Ophthalmol."},{"key":"10.1016\/j.ymgme.2025.109176_bb0345","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/WNO.0000000000001023","article-title":"Real-world clinical experience with idebenone in the treatment of Leber hereditary optic neuropathy","volume":"40","author":"Catarino","year":"2020","journal-title":"J. Neuroophthalmol."},{"key":"10.1016\/j.ymgme.2025.109176_bb0350","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/WNO.0b013e318272c643","article-title":"Effects of idebenone on color vision in patients with leber hereditary optic neuropathy","volume":"33","author":"Rudolph","year":"2013","journal-title":"J. Neuroophthalmol."},{"key":"10.1016\/j.ymgme.2025.109176_bb0355","article-title":"LEROS study group, therapeutic benefit of idebenone in patients with Leber hereditary optic neuropathy: the LEROS nonrandomized controlled trial","volume":"5","author":"Yu-Wai-Man","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.ymgme.2025.109176_bb0360","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/aos.15153","article-title":"Clinical outcomes of treatment with idebenone in Leber\u2019s hereditary optic neuropathy in the Netherlands: a national cohort study","volume":"100","author":"van Everdingen","year":"2022","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.ymgme.2025.109176_bb0365","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/heart.87.4.346","article-title":"Idebenone and reduced cardiac hypertrophy in Friedreich\u2019s ataxia","volume":"87","author":"Hausse","year":"2002","journal-title":"Heart"},{"key":"10.1016\/j.ymgme.2025.109176_bb0370","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1055\/s-2002-34494","article-title":"Friedreich\u2019s ataxia: idebenone treatment in early stage patients","volume":"33","author":"Artuch","year":"2002","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.ymgme.2025.109176_bb0375","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.ahj.2010.10.038","article-title":"Idebenone in Friedreich ataxia cardiomyopathy-results from a 6-month phase III study (IONIA)","volume":"161","author":"Lagedrost","year":"2011","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ymgme.2025.109176_bb0380","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s00415-011-6174-y","article-title":"Assessment of neurological efficacy of idebenone in pediatric patients with Friedreich\u2019s ataxia: data from a 6-month controlled study followed by a 12-month open-label extension study","volume":"259","author":"Meier","year":"2012","journal-title":"J. Neurol."},{"key":"10.1016\/j.ymgme.2025.109176_bb0385","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/aws280","article-title":"Idebenone treatment in patients with OPA1-mutant dominant optic atrophy","volume":"136","author":"Barboni","year":"2013","journal-title":"Brain"},{"key":"10.1016\/j.ymgme.2025.109176_bb0390","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1126\/science.56.1458.650","article-title":"On the existence of a hitherto unrecognized dietary factor essential for reproduction","volume":"56","author":"Evans","year":"1922","journal-title":"Science"},{"key":"10.1016\/j.ymgme.2025.109176_bb0395","doi-asserted-by":"crossref","first-page":"9961","DOI":"10.2147\/IJN.S276355","article-title":"Pharmacology and pharmacokinetics of vitamin E: Nanoformulations to enhance bioavailability","volume":"15","author":"Mohd Zaffarin","year":"2020","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ymgme.2025.109176_bb0400","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1211\/0022357011775208","article-title":"Pharmacokinetics and bioavailability of alpha-, gamma- and delta-tocotrienols under different food status","volume":"53","author":"Yap","year":"2001","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ymgme.2025.109176_bb0405","doi-asserted-by":"crossref","DOI":"10.4172\/2155-9880.1000434","article-title":"Evaluation of pharmacokinetics, and bioavailability of higher doses of tocotrienols in healthy fed humans","volume":"7","author":"Qureshi","year":"2016","journal-title":"J. Clin. Exp. Cardiolog."},{"key":"10.1016\/j.ymgme.2025.109176_bb0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.jstrokecerebrovasdis.2020.104747","article-title":"Cryptogenic intracranial hemorrhagic strokes associated with hypervitaminosis E and acutely elevated \u03b1-tocopherol levels","volume":"29","author":"Le","year":"2020","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"10.1016\/j.ymgme.2025.109176_bb0415","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000364","article-title":"Vitamin E serum levels and bleeding risk in patients receiving oral anticoagulant therapy: a retrospective cohort study","volume":"2","author":"Pastori","year":"2013","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ymgme.2025.109176_bb0420","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1194\/jlr.R032946","article-title":"Mechanisms for the prevention of vitamin E excess","volume":"54","author":"Traber","year":"2013","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.ymgme.2025.109176_bb0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e11460","article-title":"Stability of vitamin A, E, C and thiamine during storage of different powdered enteral formulas","volume":"8","author":"Yang","year":"2022","journal-title":"Heliyon"},{"key":"10.1016\/j.ymgme.2025.109176_bb0430","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/eye.2001.167","article-title":"Long-term assessment of combined vitamin a and E treatment for the prevention of retinal degeneration in abetalipoproteinaemia and hypobetalipoproteinaemia patients","volume":"15","author":"Chowers","year":"2001","journal-title":"EYE"},{"key":"10.1016\/j.ymgme.2025.109176_bb0435","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1157\/13091477","article-title":"A randomized single-blind trial of the effects of vitamins C and E in familial hypercholesterolemia","volume":"65","author":"Ald\u00e1miz-Echevarr\u00eda","year":"2006","journal-title":"An. Pediatr. (Barc.)"},{"key":"10.1016\/j.ymgme.2025.109176_bb0440","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0022-3476(98)70174-X","article-title":"Endothelial dysfunction occurs in children with two genetic hyperlipidemias: improvement with antioxidant vitamin therapy","volume":"133","author":"Mietus-Snyder","year":"1998","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2025.109176_bb0445","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1161\/01.CIR.0000086345.09861.A0","article-title":"Antioxidant vitamins C and E improve endothelial function in children with hyperlipidemia: endothelial assessment of risk from lipids in youth (EARLY) trial: endothelial assessment of risk from lipids in youth (EARLY) trial","volume":"108","author":"Engler","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ymgme.2025.109176_bb0450","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1161\/hc3501.095287","article-title":"Oxidative stress and platelet activation in homozygous homocystinuria","volume":"104","author":"Dav\u00ec","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.ymgme.2025.109176_bb0455","doi-asserted-by":"crossref","DOI":"10.1002\/jimd.12844","article-title":"Cystathionine \u03b2-synthase deficiency in the E-HOD registry-part II: dietary and pharmacological treatment","volume":"48","author":"Morris","year":"2025","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2025.109176_bb0460","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/S0022-3476(86)80833-2","article-title":"Improved erythrocyte survival with combined vitamin E and selenium therapy in children with glucose-6-phosphate dehydrogenase deficiency and mild chronic hemolysis","volume":"108","author":"Hafez","year":"1986","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2025.109176_bb0465","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/0925-4439(95)00039-7","article-title":"The treatment of mitochondrial myopathies and encephalomyopathies","volume":"1271","author":"Peterson","year":"1995","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymgme.2025.109176_bb0470","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1002\/mds.25058","article-title":"A0001 in Friedreich ataxia: biochemical characterization and effects in a clinical trial: A0001 in Friedreich Ataxia","volume":"27","author":"Lynch","year":"2012","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ymgme.2025.109176_bb0475","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s12031-016-0760-5","article-title":"Tocotrienol treatment in familial dysautonomia: Open-label pilot study","volume":"59","author":"Cheishvili","year":"2016","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.ymgme.2025.109176_bb0480","article-title":"A 6-month randomized controlled trial for vitamin E supplementation in pediatric patients with Gaucher disease: effect on oxidative stress, disease severity and hepatic complications","author":"Adly","year":"2024","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2025.109176_bb0485","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s00431-008-0889-5","article-title":"Vitamin E supplementation improves neutropenia and reduces the frequency of infections in patients with glycogen storage disease type 1b","volume":"168","author":"Melis","year":"2009","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.ymgme.2025.109176_bb0490","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1182\/blood.2019004465","article-title":"Treating neutropenia and neutrophil dysfunction in glycogen storage disease type Ib with an SGLT2 inhibitor","volume":"136","author":"Wortmann","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ymgme.2025.109176_bb0495","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2024.108144","article-title":"Treatment recommendations for glycogen storage disease type IB- associated neutropenia and neutrophil dysfunction with empagliflozin: consensus from an international workshop","volume":"141","author":"Gr\u00fcnert","year":"2024","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109176_bb0500","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3390\/nu13020615","article-title":"On behalf of the Oemonom, vitamin C-sources, physiological role, kinetics, deficiency, use, toxicity, and determination","volume":"13","author":"Dosed\u011bl","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.ymgme.2025.109176_bb0505","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1080\/10408398.2016.1264360","article-title":"Modeling the degradation kinetics of ascorbic acid","volume":"58","author":"Peleg","year":"2018","journal-title":"Crit. Rev. Food Sci. Nutr."},{"key":"10.1016\/j.ymgme.2025.109176_bb0510","doi-asserted-by":"crossref","first-page":"516","DOI":"10.3390\/nano14060516","article-title":"Enhanced stability of oral vitamin C delivery: a novel large-scale method for liposomes production and encapsulation through dynamic high-pressure microfluidization","volume":"14","author":"Romano","year":"2024","journal-title":"Nanomaterials (Basel)"},{"key":"10.1016\/j.ymgme.2025.109176_bb0515","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJM197904053001403","article-title":"Ineffectiveness of ascorbic acid therapy in nephropathic cystinosis","volume":"300","author":"Schneider","year":"1979","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2025.109176_bb0520","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1159\/000481034","article-title":"Ascorbic acid treatment in nephropathic cystinosis in identical twins","volume":"2","author":"Oberfield","year":"1981","journal-title":"Dev. Pharmacol. Ther."},{"key":"10.1016\/j.ymgme.2025.109176_bb0525","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/jmri.20162","article-title":"Ascorbate decreases Fabry cerebral hyperperfusion suggesting a reactive oxygen species abnormality: an arterial spin tagging study","volume":"20","author":"Moore","year":"2004","journal-title":"J. Magn. Reson. Imaging"},{"key":"10.1016\/j.ymgme.2025.109176_bb0530","first-page":"15","article-title":"N-acetyl-dl-leucine, medicament symptomatique des etats vertigineux","volume":"141","author":"Neuzil","year":"2002","journal-title":"Bull. Soc. Pharm. Bordeaux"},{"key":"10.1016\/j.ymgme.2025.109176_bb0535","doi-asserted-by":"crossref","first-page":"15812","DOI":"10.1038\/s41598-021-95255-5","article-title":"Acetylation turns leucine into a drug by membrane transporter switching","volume":"11","author":"Churchill","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymgme.2025.109176_bb0540","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0229585","article-title":"Unexpected differences in the pharmacokinetics of N-acetyl-DL-leucine enantiomers after oral dosing and their clinical relevance","volume":"15","author":"Churchill","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2025.109176_bb0545","doi-asserted-by":"crossref","first-page":"fcaa148","DOI":"10.1093\/braincomms\/fcaa148","article-title":"Acetyl-leucine slows disease progression in lysosomal storage disorders","volume":"3","author":"Kaya","year":"2021","journal-title":"Brain Commun."},{"key":"10.1016\/j.ymgme.2025.109176_bb0550","doi-asserted-by":"crossref","first-page":"9249","DOI":"10.1038\/s41598-021-88693-8","article-title":"N-acetyl-L-leucine improves functional recovery and attenuates cortical cell death and neuroinflammation after traumatic brain injury in mice","volume":"11","author":"Hegdekar","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymgme.2025.109176_bb0555","doi-asserted-by":"crossref","first-page":"e1072","DOI":"10.1212\/WNL.0000000000201660","article-title":"Efficacy and safety of N-acetyl-l-leucine in children and adults with GM2 gangliosidoses","volume":"100","author":"Martakis","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2025.109176_bb0560","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1007\/s00415-021-10717-0","article-title":"Efficacy and safety of N-acetyl-l-leucine in Niemann\u2013Pick disease type C","volume":"269","author":"Bremova-Ertl","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.ymgme.2025.109176_bb0565","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJMoa2310151","article-title":"Trial of N-acetyl-l-leucine in Niemann-pick disease type C","volume":"390","author":"Bremova-Ertl","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 1","key":"10.1016\/j.ymgme.2025.109176_bb0570","first-page":"1","article-title":"SSIEM annual symposium 2024, 3\u20136 September 2024","volume":"47","year":"2024","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2025.109176_bb0575","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/ki.2011.301","article-title":"Cysteamine therapy: a treatment for cystinosis, not a cure","volume":"81","author":"Cherqui","year":"2012","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymgme.2025.109176_bb0580","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/MOP.0000000000000954","article-title":"Mitochondrial medicine therapies: rationale, evidence, and dosing guidelines: rationale, evidence, and dosing guidelines","volume":"32","author":"Barcelos","year":"2020","journal-title":"Curr. Opin. Pediatr."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719225001672?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719225001672?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T07:54:22Z","timestamp":1764834862000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719225001672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":116,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S1096719225001672"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2025.109176","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antioxidant therapy in inborn metabolic diseases","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2025.109176","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109176"}}